Last reviewed · How we verify
Flumetiazid (FLUMETHIAZIDE)
Flumetiazid (generic name: FLUMETHIAZIDE) is a flumethiazide drug. It is currently in Phase 2 development for Edema, Hypertensive disorder.
Flumethiazide works by blocking the reabsorption of sodium and chloride ions in the kidneys, leading to increased urine production and reduced blood pressure.
Flumethiazide is a small molecule drug in the thiazide diuretic class, originally developed by an unknown entity and currently owned by an unknown entity. It is used to treat edema and hypertensive disorders by promoting the excretion of sodium and water in the urine. The commercial status of flumethiazide is unknown, but it is likely used as a generic medication. Key safety considerations include potential electrolyte imbalances and dehydration. As a thiazide diuretic, flumethiazide works by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidneys.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FLUMETHIAZIDE |
|---|---|
| Drug class | flumethiazide |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Imagine your kidneys as filters that remove waste and excess fluids from your blood. Flumethiazide helps these filters work more efficiently by blocking the reabsorption of sodium and chloride ions, which are essential for maintaining fluid balance in the body. This leads to increased urine production and reduced blood pressure, making it easier for the heart to pump blood and reducing the risk of complications from high blood pressure.
Approved indications
- Edema
- Hypertensive disorder
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flumetiazid CI brief — competitive landscape report
- Flumetiazid updates RSS · CI watch RSS
Frequently asked questions about Flumetiazid
What is Flumetiazid?
How does Flumetiazid work?
What is Flumetiazid used for?
What is the generic name of Flumetiazid?
What drug class is Flumetiazid in?
What development phase is Flumetiazid in?
Related
- Drug class: All flumethiazide drugs
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Edema
- Indication: Drugs for Hypertensive disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing